Tirzepatide has potential to drive weight loss market dramatically, observes GlobalData
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
The new hospital is expected to open by March'24
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
For the first time in India – fast, precise and efficient calibration of multi-channel micropipettes
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated